Anti-obesity weight loss medications: Short-term and long-term use.


Journal

Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521

Informations de publication

Date de publication:
01 Oct 2022
Historique:
received: 06 06 2022
revised: 13 07 2022
accepted: 15 07 2022
pubmed: 24 7 2022
medline: 24 8 2022
entrez: 23 7 2022
Statut: ppublish

Résumé

As obesity prevalence increases, more and more drugs that assist with weight loss have been developed. Numerous weight loss drugs had been approved, but many have also been withdrawn based on their lack of efficacy as well as safety concerns. Initial approaches in developing weight loss drugs was by increasing physiological energy expenditure and suppressing the appetite. Subsequently, as more physiological mechanisms for weight gain has been unearthed, drugs targeting newly discovered receptors and/or enzymes have been introduced with improved safety profiles and fewer psychological adverse events. Additionally, drugs targeting hunger or satiety signaling have been actively studied, and have shown increased adoption by physicians. Studies have also evaluated drugs that target metabolic tissues-such as adipose tissue or muscle-to promote weight loss, however to-date nothing has carried on into clinical practice. Starting with a brief history of early obesity treatments, this review evaluates current weight loss pharmaceutical options based on their duration of therapy status.

Identifiants

pubmed: 35870619
pii: S0024-3205(22)00525-2
doi: 10.1016/j.lfs.2022.120825
pii:
doi:

Substances chimiques

Anti-Obesity Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

120825

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Dagam Jeong (D)

Massachusetts College of Pharmacy and Health Sciences, Boston, MA 02115, United States of America.

Ronny Priefer (R)

Massachusetts College of Pharmacy and Health Sciences, Boston, MA 02115, United States of America. Electronic address: ronny.priefer@mcphs.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH